Trial Design and Patients
breast cancer, a stage 0-III disease, Cancer
FEMALE BREAST CANCER, BREAST CANCER, ONCOLOGY, CANCER
We conducted a single-center, parallel-group, open-label, randomized controlled trial at Asan Medical Center (Seoul, Republic of Korea). Inclusion criteria were female breast cancer survivors aged 20 to 60 years with a stage 0-III disease based on the 7th edition of the American Joint Committee on Cancer Staging Manual and Eastern Cooperative Oncology Group Performance Status 0. Older patients were excluded from the study due to potential challenges they may face in using smartphone apps and reading small fonts, as required by the study protocol. Eligible participants were those capable of using their own smartphones compatible with the Android-based app WalkON (Swallaby Co, Ltd), which is a freely available app that was modified for this study [Between January 7, 2019, and April 17, 2020, we consecutively assessed 2616 patients with breast cancer who underwent surgery (Study enrollment flow chart.